Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task
File version
Author(s)
Zhang, Lu
Yang, Xiaodan
Li, Hejie
Ma, Bowei
Walton, Shelley
Wu, Xiaolian
Yuan, Jianwei
Wang, Tianfang
Liu, Xiaosong
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Interleukin 10 (IL-10) belongs to IL-10 family cytokines that are critical for maintaining the integrity of epithelial tissues, protecting pathogenic infection, and preventing excessive immune responses to damage self. Temporal IL-10 signaling blockade enhances vaccine-induced tumor regression by CD8 + T cells. IL-10, especially pegylated IL-10, mediates tumor regression by expanding tumor-infiltrating CD8 + T cells. Moreover, targeting IL-10 enhances immune checkpoint inhibitor mediated tumor regression. In the current paper, we will review recent advances in this area and discuss the complexity of IL-10 manipulation for cancer therapy.
Journal Title
Human Vaccines & Immunotherapeutics
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
This publication has been entered in Griffith Research Online as an advanced online version.
Access the data
Related item(s)
Subject
Immunology
Medical microbiology
Pharmacology and pharmaceutical sciences
Science & Technology
Life Sciences & Biomedicine
Biotechnology & Applied Microbiology
Interleukin 10
Persistent link to this record
Citation
Ni, G; Zhang, L; Yang, X; Li, H; Ma, B; Walton, S; Wu, X; Yuan, J; Wang, T; Liu, X, Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task, Human Vaccines & Immunotherapeutics, 2020